Autonomic Disorders Certification Examination Committee Contributors
Paola Sandroni, MD, PhD, Mayo Clinic - Rochester
Disclosures: Nothing to disclose.
William P. Cheshire, MD, Mayo Clinic - Jacksonville
Disclosures: Received reimbursement from Wolters Kluwer for writing for UpToDate; Received research support in the form of travel reimbursement from Biohaven to attend research investigators’ meeting.
Elizabeth Coon, MD, Mayo Clinic – Rochester
Disclosures: Nothing to disclose.
Roy L. Freeman, MD, Beth Israel Deaconess Hospital
Disclosures: Received personal compensation and/or stock options for serving on scientific advisory boards of: Abide, Applied Therapeutics, Astellas, Aptinyx, Biogen, Biohaven, Cutaneous NeuroDiagnostics, GW Pharma, Ironwood, Lundbeck, MundiPharma, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray, Theravance and Vertex; Holds stock or stock options for NeuroBo as chair of the scientific advisory board; Received research support from Biogen for quality control of skin biopsy data, from Theravance for trials and study for orthostatic hypotension trial. Received research support from Biohaven for trial of multiple system atrophy.
David S. Goldstein, MD, PhD, NINDS, NIH
Disclosures: Received research funding from the United States government.
Phillip A. Low, MD, FAAN, Mayo Clinic – Rochester
Disclosures: Received personal compensation from WR Medical for consultant services.
Peter Novak, MD, PhD, Brigham and Women's Faulkner Hospital
Disclosures: Received personal compensation as Advisor - independent contractor for Dysimmune Diseases Foundation. Member of Scientific Advisory Board for Endonovo Therapeutics. Received royalties for authored book, Autonomic Testing; Holds stock in Pfizer.
Brian Olshansky, MD, University of Iowa Hospitals and Clinics
Disclosures: Received personal compensation from Boehringer Ingelheim, Lundbeck, Amarin, Sanofi-Aventis, and Respironics for consultant services.
Lauren Phillips, MD, UT Southwestern Medical School
Disclosures: Received personal compensation as a consultant for ACI Clinical - Neurology Endpoint Adjudication Committee; Received research support from NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials) funded by National Institute of Health’s National Institute of Neurological Disorders and Stroke (NINDS) for project: Topirimate as a Disease Altering Therapy for role as for Cryptogenic Sensory Peripheral Neuropathy (CSPN) [NN108 TopCSPN], role as site principal investigator; Received research support from Grifols Pharmaceuticals (Industry) for project: Dysautonomia International Title of Project: iSTAND: IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS), Role: Co-Investigator.